Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, et al
The impact we are seeing in OA might be real, but we have to define it more clearly. Although no data are conclusive yet, preclinical studies have shown that GLP-1 receptor agonists can inhibit the NF-kB pathway, a key pathway involved in inflammation and cartilage destruction, according to Lane
Tirzepatides cardiovascular outcome trial is ongoing but expected to show benefit
OZEMPIC should be injected once a week , at any time of day, and can be administered with or without food
2,3 Because of this, we aimed to further investigate the effects on weight after discontinuing semaglutide or liraglutide